AMIR A JAZAERI

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep. 2021 02 11; 11(1):3667. PMID: 33574401.
      Citations:    Fields:    
    2. Fix SM, Jazaeri AA, Hwu P. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. Cancer Discov. 2021 Feb 09. PMID: 33563662.
      Citations:    Fields:    
    3. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 Jan 07. PMID: 33415580.
      Citations:    Fields:    
    4. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 Jan; 31(1):92-97. PMID: 33154095.
      Citations:    Fields:    
    5. Hinchcliff E, Gunther J, Ponnie AE, Bednarski B, Onstad M, Shafer A, Frumovitz M, Jazaeri A, Urbauer D, Bodurka DC. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. J Cancer Educ. 2020 Aug 25. PMID: 32839894.
      Citations:    Fields:    
    6. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 Sep; 158(3):570-575. PMID: 32534809.
      Citations:    Fields:    
    7. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502. PMID: 32294438.
      Citations: 3     Fields:    
    8. Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 04; 157(1):161-166. PMID: 31924334.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    9. How J, Patel A, Jazaeri A. Immuno-oncology for Gynecologic Malignancies. Adv Exp Med Biol. 2020; 1244:149-182. PMID: 32301014.
      Citations: 1     Fields:    Translation:Humans
    10. Hinchcliff E, Jazaeri AA. Sunset, or dawn of a new age for ovarian cancer vaccine therapy? Gynecol Oncol. 2019 12; 155(3):387-388. PMID: 31812214.
      Citations:    Fields:    Translation:Humans
    11. Roelands J, Garand M, Hinchcliff E, Ma Y, Shah P, Toufiq M, Alfaki M, Hendrickx W, Boughorbel S, Rinchai D, Jazaeri A, Bedognetti D, Chaussabel D. Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. Front Immunol. 2019; 10:2410. PMID: 31681299.
      Citations: 2     Fields:    Translation:HumansCells
    12. Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother. 2019 Nov; 68(11):1747-1757. PMID: 31602489.
      Citations: 1     Fields:    Translation:HumansCells
    13. Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR, Klopp A. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244. PMID: 31500892.
      Citations: 3     Fields:    Translation:Humans
    14. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. 2019 Sep; 68(9):1515-1526. PMID: 31515669.
      Citations: 1     Fields:    Translation:HumansCells
    15. Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA. B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecol Oncol Rep. 2019 Aug; 29:94-97. PMID: 31467959.
      Citations:    
    16. Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, Difeo A, Scacheri PC, Adli M. Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. Cancer Res. 2019 09 15; 79(18):4599-4611. PMID: 31358529.
      Citations: 2     Fields:    Translation:HumansCells
    17. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer. 2019 05 03; 7(1):118. PMID: 31053161.
      Citations:    Fields:    Translation:Humans
    18. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019 04 02; 7(1):93. PMID: 30940209.
      Citations: 17     Fields:    Translation:Humans
    19. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019 02 06; 7(1):31. PMID: 30728076.
      Citations: 4     Fields:    Translation:Humans
    20. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413. PMID: 30366646.
      Citations: 4     Fields:    Translation:Humans
    21. Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102. PMID: 30283446.
      Citations: 5     Fields:    Translation:HumansCells
    22. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435.
      Citations:    Fields:    Translation:Humans
    23. Johnson C, Jazaeri AA. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Clin Ther. 2018 03; 40(3):389-394. PMID: 29519715.
      Citations: 3     Fields:    Translation:Humans
    24. Jazaeri AA. Immunotherapy in ovarian cancer: where are we now, and where are we going? Clin Adv Hematol Oncol. 2017 Nov; 15(11):851-853. PMID: 29200418.
      Citations: 1     Fields:    Translation:Humans
    25. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086. PMID: 28901560.
      Citations: 7     Fields:    Translation:Humans
    26. Pakish JB, Jazaeri AA. Immunotherapy in Gynecologic Cancers: Are We There Yet? Curr Treat Options Oncol. 2017 08 24; 18(10):59. PMID: 28840453.
      Citations: 14     Fields:    Translation:Humans
    27. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689. PMID: 28670312.
      Citations: 15     Fields:    
    28. Nelson BH, Jazaeri AA. Immunotherapy for gynecological cancers: opportunities abound. Gynecol Oncol. 2017 06; 145(3):411-412. PMID: 28552394.
      Citations:    Fields:    Translation:Humans
    29. Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A. Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation. Mol Cancer Res. 2017 09; 15(9):1197-1205. PMID: 28550083.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    30. Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 May; 20:93-96. PMID: 28393092.
      Citations:    
    31. Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2017 02 28; 8(9):16099. PMID: 28403580.
      Citations:    Fields:    
    32. Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol. 2017 06; 145(3):462-468. PMID: 28233576.
      Citations: 5     Fields:    Translation:HumansCells
    33. Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016 09 30; 35(22):3892-906. PMID: 27112322.
      Citations: 5     Fields:    Translation:Humans
    34. Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol. 2016 Apr; 141(1):86-94. PMID: 27016233.
      Citations: 12     Fields:    Translation:HumansCells
    35. Ring KL, Pakish J, Jazaeri AA. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer J. 2016 Mar-Apr; 22(2):101-7. PMID: 27111905.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    36. Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA, Huang Z, Murphy SK, Mythreye K. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia. 2015 Nov; 17(11):826-38. PMID: 26678910.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    37. Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2015 Oct 06; 6(30):30194-211. PMID: 26327203.
      Citations: 3     Fields:    Translation:HumansCells
    38. Qiao Y, Quinlan AR, Jazaeri AA, Verhaak RG, Wheeler DA, Marth GT. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol. 2014 Aug 26; 15(8):443. PMID: 25160522.
      Citations: 26     Fields:    Translation:HumansCells
    39. Jividen K, Movassagh MJ, Jazaeri A, Li H. Two methods for establishing primary human endometrial stromal cells from hysterectomy specimens. J Vis Exp. 2014 May 23; (87). PMID: 24894444.
      Citations: 5     Fields:    Translation:HumansCells
    40. Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, Slack-Davis JK. Inhibition of a4ß1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol. 2014 Feb; 132(2):455-61. PMID: 24378876.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    41. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. . 2013 Oct; 12(10):1958-67. PMID: 23939375.
      Citations:    
    42. Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, Jazaeri AA, Cantrell LA, Duska LR. Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. Gynecol Oncol Case Rep. 2013; 5:6-9. PMID: 24371682.
      Citations:    
    43. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 2013 Jul 04; 32(27):3246-53. PMID: 22890324.
      Citations: 48     Fields:    Translation:HumansCells
    44. Bae-Jump V, Jazaeri A. Summary of the 2012 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2012 Aug; 126(2):174-5. PMID: 22588179.
      Citations:    Fields:    Translation:Humans
    45. Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA. Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol. 2012 Jul; 126(1):20-4. PMID: 22522190.
      Citations: 25     Fields:    Translation:Humans
    46. Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia. 2011 Oct; 13(10):899-911. PMID: 22028616.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    47. Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol. 2011 Apr; 121(1):2-7. PMID: 21269667.
      Citations: 4     Fields:    Translation:Humans
    48. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA. Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol. 2010 Dec; 116(6):1348-1353. PMID: 21099601.
      Citations: 5     Fields:    Translation:Humans
    49. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. . 2010 Nov 01; 9(21):4387-98. PMID: 20980827.
      Citations:    
    50. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol. 2010 Aug 01; 118(2):189-95. PMID: 20462630.
      Citations: 6     Fields:    Translation:HumansCells
    51. Terai K, Abbas T, Jazaeri AA, Dutta A. CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell. 2010 Jan 15; 37(1):143-9. PMID: 20129063.
      Citations: 70     Fields:    Translation:HumansCells
    52. Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, Jazaeri AA. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer. 2010 Jan; 20(1):120-5. PMID: 20130512.
      Citations: 3     Fields:    Translation:Humans
    53. Jazaeri AA, Slack-Davis JK. The promise of antiangiogenic therapy for ovarian cancer. . 2009 Dec; 8(23):2273-4. PMID: 19907207.
      Citations:    
    54. Greene DP, Ferriss JS, Jazaeri AA. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother Pharmacol. 2010 Jul; 66(2):265-7. PMID: 19844714.
      Citations: 2     Fields:    Translation:Humans
    55. Jazaeri AA. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol. 2009 Apr; 3(2):151-6. PMID: 19383376.
      Citations: 4     Fields:    Translation:Humans
    56. Bland AE, Stone R, Heuser C, Shu J, Jazaeri A, Shutter J, Atkins K, Rice L. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer. 2009 Feb; 19(2):261-5. PMID: 19396006.
      Citations: 9     Fields:    Translation:Humans
    57. Lachance JA, Shutter J, Atkins KA, Stoler MH, Rice LW, Jazaeri AA. Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol. 2008 Aug; 199(2):189.e1-6. PMID: 18501326.
      Citations: 2     Fields:    Translation:Humans
    58. Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost comparison of two strategies for treating stage IB2 cervical cancer. Int J Gynecol Cancer. 2008 Mar-Apr; 18(2):274-8. PMID: 18334009.
      Citations: 1     Fields:    Translation:Humans
    59. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol. 2008 Apr; 109(1):140-5. PMID: 18275990.
      Citations: 12     Fields:    Translation:Humans
    60. Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol. 2008 Jan; 108(1):77-83. PMID: 17936341.
      Citations: 4     Fields:    Translation:Humans
    61. Darus CJ, Callahan MB, Nguyen QN, Pastore LM, Schneider BF, Rice LW, Jazaeri AA. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):730-5. PMID: 17949426.
      Citations: 5     Fields:    Translation:Humans
    62. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother. 2007 Oct; 8(14):2293-305. PMID: 17927484.
      Citations: 8     Fields:    Translation:Humans
    63. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PMID: 17689649.
      Citations: 3     Fields:    Translation:Humans
    64. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol. 2007 Aug; 197(2):195.e1-7; discussion 195.e7-8. PMID: 17689647.
      Citations: 2     Fields:    Translation:Humans
    65. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol. 2006 Aug; 195(2):568-74; discussion 574-6. PMID: 16890558.
      Citations: 7     Fields:    Translation:Humans
    66. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol. 2006 Apr; 194(4):1119-26; discussion 1126-8. PMID: 16580307.
      Citations: 5     Fields:    Translation:HumansCells
    67. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10. PMID: 16144934.
      Citations: 58     Fields:    Translation:Humans
    68. Irvin W, Evans SR, Andersen W, Jazaeri A, Taylor P, Stoler M, Pastore L, Rice L. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol. 2005 Aug; 193(2):559-65; discussion 565-7. PMID: 16098895.
      Citations: 2     Fields:    Translation:HumansCells
    69. Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. J Transl Med. 2004 Sep 21; 2(1):32. PMID: 15383145.
      Citations: 6     Fields:    
    70. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 2003 Oct 15; 9(13):4811-8. PMID: 14581352.
      Citations: 35     Fields:    Translation:HumansCells
    71. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10393-8. PMID: 12917485.
      Citations: 595     Fields:    Translation:Humans
    72. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog. 2003 Feb; 36(2):53-9. PMID: 12557260.
      Citations: 11     Fields:    Translation:Humans
    73. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003 Jan 01; 63(1):6-11. PMID: 12517768.
      Citations: 55     Fields:    Translation:Humans
    74. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002 Jul 03; 94(13):990-1000. PMID: 12096084.
      Citations: 66     Fields:    Translation:Humans
    75. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002; 4(3):R3. PMID: 12052255.
      Citations: 46     Fields:    Translation:Humans
    76. Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn. 2002 Feb; 4(1):30-6. PMID: 11826185.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    77. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001 Oct 18; 20(47):6965-9. PMID: 11687977.
      Citations: 9     Fields:    Translation:Humans
    78. Jazaeri A, Satija II. Localization transition in incommensurate non-Hermitian systems. Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Mar; 63(3 Pt 2):036222. PMID: 11308756.
      Citations:    Fields:    
    79. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000 Jan 15; 60(2):245-8. PMID: 10667568.
      Citations: 80     Fields:    Translation:Humans
    80. Jazaeri O, Shupnik MA, Jazaeri AA, Rice LW. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol. 1999 Jul; 74(1):38-47. PMID: 10385549.
      Citations: 5     Fields:    Translation:Humans
    81. Rice LW, Jazaeri AA, Shupnik MA. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Gynecol Oncol. 1997 Apr; 65(1):149-57. PMID: 9103405.
      Citations: 3     Fields:    Translation:HumansCells
    82. Philpot BD, Jazaeri AA, Brunjes PC. The development of serotonergic projections to the olfactory bulb of Monodelphis domestica (the grey, short-tailed opossum). Brain Res Dev Brain Res. 1994 Feb 18; 77(2):265-70. PMID: 8174233.
      Citations: 1     Fields:    Translation:AnimalsCells
    83. Brunjes PC, Jazaeri A, Sutherland MJ. Olfactory bulb organization and development in Monodelphis domestica (grey short-tailed opossum). J Comp Neurol. 1992 Jun 22; 320(4):544-54. PMID: 1378458.
      Citations: 4     Fields:    Translation:AnimalsCells
    84. Frailty. Obstetrical and Gynecological Survey. 68:30-32.
    85. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia (United States). 17:826-838.
    86. Immune checkpoint inhibitors in the treatment of gynecologic malignancies. Cancer Journal (United States). 22:101-107.
    87. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology. 141:86-94.
    88. BRCA1-mediated repression of select X chromosome genes. Journal of Translational Medicine. 2.
    89. Vulvar necrotizing soft tissue infection. Gynecologic Oncology Case Reports. 5:6-9.
    90. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 6:30194-30211.
    JAZAERI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (342)
    Explore
    _
    Co-Authors (61)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _